Three novel pentavalent meningococcal vaccines-Reference-Cited by-同舟云学术

Three novel pentavalent meningococcal vaccines

Published:2023-11-25 Issue:1 Volume:31 Page:
ISSN:1195-1982
Container-title:Journal of Travel Medicine
language:en
Short-container-title:

Author:

Steffen Robert¹²³⁴,Caumes Eric⁵⁶

Affiliation:

1. Epidemiology , Biostatistics and Prevention Institute, Department of Public and Global Health, Division of Infectious Diseases, World Health Organization Collaborating Centre for Travelers’ Health, , Zurich , Switzerland

2. University of Zurich , Biostatistics and Prevention Institute, Department of Public and Global Health, Division of Infectious Diseases, World Health Organization Collaborating Centre for Travelers’ Health, , Zurich , Switzerland

3. Division of Epidemiology , Human Genetics & Environmental Sciences, , Houston, TX , USA

4. University of Texas School of Public Health , Human Genetics & Environmental Sciences, , Houston, TX , USA

5. Infectious and Tropical Diseases, Sorbonne University , Paris , France

6. Centre de diagnostic et de thérapeutique, Hôpital de l’Hôtel-Dieu. , Paris , France

Abstract

Invasive meningococcal disease (IMD) is rare in travellers but associated with high mortality and long-term sequelae. Six serogroups (MenABCWXY) account for more than 90% of IMD. Three pentavalent vaccines are on the horizon: two MenABCWY, both with a 0–6 month schedule, highly immunogenic and well tolerated, and one single-dose MenACWXY.

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

https://academic.oup.com/jtm/advance-article-pdf/doi/10.1093/jtm/taad152/54705267/taad152.pdf

Reference12 articles.

1. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations;Acevedo;Expert Rev Vaccines,2019

2. Carriage of Neisseria meningitidis among travelers attending the Hajj pilgrimage, circulating serogroups, sequence types and antimicrobial susceptibility: a multinational longitudinal cohort study;Yezli;Travel Med Infect Dis,2023

3. One-year sequelae and quality of life in adults with meningococcal meningitis: lessons from the COMBAT Multicentre Prospective Study;Duval;Adv Ther,2022

4. Efficacy and effectiveness of the meningococcal conjugate Group A vaccine MenAfriVac® in preventing recurrent meningitis epidemics in Sub-Saharan Africa;Viviani;Vaccine,2022

5. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomized trial;Peterson;Lancet Infect Dis,2023